|
|
Post by RLC on Jan 6, 2015 14:02:07 GMT
I was going to ask you the same question  I really don't know what's going to happen, but I'll go on record saying that if the data is great and falls along the lines of interim data, which I don't see why it won't, then I would be disappointed if it does not at least double up from here. $12 is what I am hoping for, but as we just saw with BCLI, some of these unknown companies with extremely low floats can skyrocket on big news. The market for WF10 is so big that I am guilty of letting myself dream a bit with this one too, lol. I am thinking we'll start to see the volume pick up a bit and pps start to creep up as we get closer to/into February. There's a lot to like here: - Good cash position
- Low MC.... P/E of only 1.7
- Major near term catalyst (obviously being release of WF10 Phase 2 data in mid-February)
- Multiple other opportunities for revenue generation (Pennsaid 2%, collaboration w/ Ferndale Labs, etc.)
I dug this research report up from August of 2014 that pretty much summarized how I feel about the company, especially the "low risk with the potential for a large upside with success of WF10" part: "Nothing has materially changed since we initiated coverage of Nuvo approximately 3 months ago, thus we are continuing to rate the stock a Buy with a $7.50 price target. We see an investment in Nuvo as relatively low risk with the potential for a large upside should the clinical trial for WF10 succeed. Potential catalysts coming up in the second half of the year that could drive the stock price higher are a run up leading up to the release of the WF10 Phase 2 data in early 2015 and any positive news surrounding the litigation with Mallinckrodt around Pennsaid® 2%. Our valuation is derived from a sum-of-parts where we see the cash balance and Pennsaid® royalties supporting the current valuation, along with meaningful potential upside from regaining Pennsaid® 2% rights and WF10."
This guy was spot on when this article was written, as the stock is up almost 100% since then. |
|
|
|
Post by Yelk on Jan 10, 2015 22:32:49 GMT
I noticed some posts in this thread in regard to Liquidity - selling and buying. Am I missing something or has anyone noticed this is traded on TSX (NRI) and has almost twice the 10 day trade volume? It appears to be the same company. I'm Canadian and was blown away after reading through this thread, their website, other sources and news. Just about to establish a position in this company and wanted to avoid OTC if possible. Something to consider moving forward.
|
|
|
|
Post by JHam on Jan 10, 2015 22:51:10 GMT
I noticed some posts in this thread in regard to Liquidity - selling and buying. Am I missing something or has anyone noticed this is traded on TSX (NRI) and has almost twice the 10 day trade volume? It appears to be the same company. I'm Canadian and was blown away after reading through this thread, their website, other sources and news. Just about to establish a position in this company and wanted to avoid OTC if possible. Something to consider moving forward. Yes we talked about this here: thebiotechinvestor.freeforums.net/post/9131/threadIn short, I would prefer to be holding NRI instead of NRIFF. I tried to transfer my funds from NRIFF to NRI last year, but after I sold my NRIFF position, I realized I couldn't buy shares on the TSX. So I went back to NRIFF. NRI is traded like a normal stock on the TSX and is personally what I would rather own if I could. I notice that while both stocks don't trade exactly the same every day, that they usually reflect similar movement over a few days time. For example, NRI may go up 7% one day and then down 3% the next day for a 4% gain over two days. While NRIFF may go up 1% one day and then 3% the next day for a 4% gain over two days. Not always, but it does seem to equal out. This is is the stock I am most anxious about right now. It is still trading basically at cash levels ($60M MC) and we are only weeks from finding out whether or not they have a superior treatment with WF10. A potential $10B market in the USA alone. |
|
|
|
Post by JHam on Jan 10, 2015 23:07:03 GMT
Incidentally, they had an independent study done which stated they felt Nuvo could capture $700M-$1.1B of the USA market. I know that wouldn't immediately translate into market valuation if they release positive trial results, but jeeze think about what $1B in revenue does for a stock with 10.6M shares outstanding. Especially from the current market cap levels. I'll definitely be taking some off the table when they release data results, but I may keep a small position for the long haul. Just lock it away, forget about it, and take a look again in a year or two and see where we are.
|
|
|
|
Post by JHam on Jan 10, 2015 23:19:43 GMT
|
|
|
|
Post by JHam on Jan 10, 2015 23:20:28 GMT
Looks like they had $60M in cash at the end of December, so it is true that they are trading at cash level.
|
|
|
|
Post by Yelk on Jan 11, 2015 5:32:44 GMT
Very impressive catalysts both short and long term with mitigated risk for the cash. I don't really feel too bad joining on a rally as I expect as well if all goes well should climb substantially above 6 as we move into 2015. Thanks for the post Jham I must have skipped that page when reading through the thread regarding TSX exchange trading. Goodluck to all holders with this one, I think we have some interesting times ahead of us.
|
|
|
|
Post by JHam on Jan 11, 2015 6:01:00 GMT
Here is a updated fact sheet on where we stand: - $60M in cash end of December - $63M market cap as of Friday - 10.62M shares outstanding - Phase 2 final data results for WF10 trial due mid-February - WF10 is used to treat Allergic Rhinitis which represents a $10B market in the USA alone - An independent study recently concluded that WF10 could capture $0.7-$1.1B of that market Here is the latest presentation from December: www.nuvoresearch.com/wp-content/uploads/2014/12/2014-12-23_Nuvo_IR_Presentation_December_2014.pdf |
|
|
|
Post by Yelk on Jan 12, 2015 0:48:12 GMT
I hope the volume tomorrow allows me to get the position I need for the right price. I'll be using TSX. JHam what potential downside you think we are looking at if unfavorable data mid Feb? Even though we are sitting at cash I can see it topple a bit. I don't feel more than a 10-15%. Although if it sky-rockets before Feb on speculation that question would be a tough one to answer so maybe it is too hard to foresee at the moment.
|
|
|
|
Post by RLC on Jan 12, 2015 4:56:37 GMT
I hope the volume tomorrow allows me to get the position I need for the right price. I'll be using TSX. JHam what potential downside you think we are looking at if unfavorable data mid Feb? Even though we are sitting at cash I can see it topple a bit. I don't feel more than a 10-15%. Although if it sky-rockets before Feb on speculation that question would be a tough one to answer so maybe it is too hard to foresee at the moment. I don't think you have anything to worry about if you're able to trade it on the TSX, unless you're wanting to make some huge purchases. NRI trades an average of 30,000+ shares/day. It's us trading on the OTC (NRIFF) that have to worry about liquidity. All 3 purchases I've made I've had to pay over the ask or accept fewer shares than I was wanting to purchase. I think it's safe to say that we'll be seeing volume pick up pretty soon as we're approaching the 1 month until TLD is released mark. Good luck on the buy tomorrow! |
|
|
|
Post by JHam on Jan 12, 2015 23:01:45 GMT
Added a chunk at $5.99 today. Now we wait.
|
|
|
|
Post by Yelk on Jan 13, 2015 3:05:30 GMT
That high today was me buying in at market bid seconds into open, forgot to limit my order. Good thing it wasn't a huge order. I had to take off for work and wanted to get in so didn't mind but cost me probably $80 because i didn't limit lol.
|
|
|
|
Post by JHam on Jan 13, 2015 9:32:39 GMT
I just noticed this slide from the last presentation. I like the comparisons to Circassia and their $1B market cap. Heck, I'd be thrilled with even a $300M market cap, as that would translate into a $28 share price.
|
|
|
|
Post by JHam on Jan 13, 2015 9:33:32 GMT
|
|
|
|
Post by JHam on Jan 13, 2015 9:34:18 GMT
Sorry I was having trouble attaching the slide along with a post from my iPad.
|
|
|
|
Post by JHam on Jan 14, 2015 0:53:04 GMT
Another example of NRIFF going higher than NRI today and making up the difference from being lower than NRI the day before.
|
|
|
|
Post by Yelk on Jan 14, 2015 1:54:12 GMT
I have noticed the same with other stocks that I have that are traded on both Canadian and U.S. exchanges. But the long term chart is literally identical. NRIFF is one of my largest positions aside from ATHX if it goes down anymore I may not be able to help myself but to add and take away from other stocks. Already drained out my BCLI totally now.
|
|
|
|
Post by Yelk on Jan 14, 2015 4:49:04 GMT
www.midasletter.com/2014/12/uvo-research-inc-tsxnri-ceo-john-london-podcast-interview/Dec 11, so a month ago but very interesting conversation with CEO. I paid very close attention to his reaction of what they would do with the money now that they had it. There seemed to be good response to fund phase II and III for WF10 moving forward. I really can't find any new material we haven't already uncovered in this thread so I guess at this point we wait.
|
|
|
|
Post by RLC on Jan 14, 2015 17:49:51 GMT
Just added another 500 shares @ $5.88 and am going to try to continue adding as long as its under $6.
|
|
|
|
Post by RLC on Jan 14, 2015 17:53:08 GMT
Just added another 500 shares @ $5.88 and am going to try to continue adding as long as its under $6. And just added another 500 shares to my IRA @ $5.86! |
|
